Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
Survivorship in metastatic prostate cancer is seen as chronic management, focusing on quality of life through physical and emotional management. Carotuximab combined with Erleada shows a favorable ...
Hosted on MSN
Key Information For Patients To Evaluate Prostate Cancer Treatment Options: Stage & Type Matter
Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...
Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.
Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results